Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 8/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.44 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.43 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.41 |
| ▸ | CHRNG | P07510 | 1/20 | 0.41 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.41 |
| ▸ | CHRND | Q07001 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9772173 | 1.00 | GRIA1 (0.47) | GRIA1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL9772156 | 1.00 | GRIA1 (0.47) | GRIA1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL9688242 | 1.00 | GRIA1 (0.47) | GRIA1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Gusperimus SCHEMBL8656104 | 1.00 | GRIA1 (0.47) | GRIA1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL25482108 | 0.99 | GRIA1 (0.46) | GRIA1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Gusperimus SCHEMBL12980163 | 0.99 | GRIA1 (0.46) | GRIA1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Gusperimus SCHEMBL26925 | 0.99 | GRIA1 (0.46) | GRIA1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Gusperimus SCHEMBL317912 | 0.99 | GRIA1 (0.46) | GRIA1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Hydrochloric Acid SCHEMBL9772186 | 0.99 | GRIA1 (0.46) | GRIA1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Hydrochloric Acid SCHEMBL9772231 | 0.99 | GRIA1 (0.46) | GRIA1CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12914 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745155-A1 | POWDER CONTAINING PARTICLES OF GELATIN DERIVATIVE AND APPLICATION OF SAME IN MEDICAL TREATMENT | National Institute for Materials Science (JP) | 2026-05-20 | — | — | EP | claimed |
| US-12571044-B2 | Classifier for identification of robust sepsis subtypes | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-03-10 | — | — | US | claimed |
| US-20250295638-A1 | METHODS OF TREATING ALLOGRAFT REJECTION | BARGENT THERAPEUTICS PTY LTD (AU) | 2025-09-25 | — | — | US | claimed |
| EP-4578454-A1 | COMPOSITIONS COMPRISING PLATELET DERIVED EXTRACELLULAR VESICLES | Lysatpharma GmbH (DE) | 2025-07-02 | — | — | EP | claimed |
| EP-4518857-A1 | METHODS OF TREATING ALLOGRAFT REJECTION | Bargent Therapeutics Pty Limited (AU) | 2025-03-12 | — | — | EP | claimed |
| WO-2025029671-A1 | CELL THERAPY FOR DIABETES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-02-06 | — | — | WO | claimed |
| WO-2025013818-A1 | POWDER CONTAINING PARTICLES OF GELATIN DERIVATIVE AND APPLICATION OF SAME IN MEDICAL TREATMENT | 国立研究開発法人物質・材料研究機構 | 2025-01-16 | — | — | WO | claimed |
| EP-4473088-A2 | CELL THERAPY FOR DIABETES | Vertex Pharmaceuticals Incorporated (US) | 2024-12-11 | — | — | EP | claimed |
| EP-3773563-B1 | PRODRUGS OF FUSED-BICYCLIC C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2024-10-16 | — | — | EP | claimed |
| CN-118354776-A | Methods and compositions for enhanced efficacy and reduced toxicity of non-implanted CD8 depleted allogeneic donor lymphocyte infusions | 约翰霍普金斯大学 | 2024-07-16 | — | — | CN | claimed |
| WO-1995015770-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-06-15 | — | — | WO | claimed |
| WO-1995001786-A1 | PHARMACEUTICAL COMPOSITIONS FOR HARDLY SOLUBLE ACTIVE SUBSTANCES | CIBA-GEIGY AG (CH) | 1995-01-19 | — | — | WO | claimed |
| EP-0359347-B1 | COVALENTLY-LINKED COMPLEXES AND METHODS FOR ENHANCED CYTOTOXICITY AND IMAGING | NEORX CORPORATION (US) | 1992-12-23 | — | — | EP | claimed |
| CN-1017621-B | Process for preparing crystalline deoxyspergualin | TAKARA SHIY ZOU CO LTD (JP) | 1992-07-29 | — | — | CN | claimed |
| CN-1047670-A | Crystalline deoxyspergualin (deoxyspergualin) and preparation method thereof | TAKARA SHIY ZOU CO LTD (JP) | 1990-12-12 | — | — | CN | claimed |
| EP-0400889-A1 | Crystalline deoxyspergualin and process for its preparation | TAKARA SHUZO CO. LTD. (JP) | 1990-12-05 | — | — | EP | claimed |
| EP-0359347-A2 | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging | NEORX CORPORATION (US) | 1990-03-21 | — | — | EP | claimed |
| US-4876244-A | STABILIZERS OF DEXTRANS, CYCLODEXTRINS, AND CHONDROITIN SULFATE; ANTICARCINOGENIC AGENTS, IMMUNOMODULATORS | ZAIDAN HOJIN BISEIBUTSU KAGAKU (JP) | 1989-10-24 | — | — | US | claimed |
| US-4710517-A | MALTOSE, LACTOSE STABILIZERS; ANTICARCINOGENIC AGENTS, IMMUNOMODULATORS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1987-12-01 | — | — | US | claimed |
| US-4518532-A | ANTITIMOR | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1985-05-21 | — | — | US | claimed |